We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Life Sciences

  • June 18, 2018

    Feds Downplay Testimony From Ex-Katten Atty's Loss Expert

    Brooklyn federal prosecutors sought to counter a bid by former Katten Muchin Rosenman LLP attorney Evan Greebel to reduce his potential sentence for fraud conspiracy on Monday, asking an expert witness questions that seemed meant to diminish his testimony on legal issues faced by life sciences startups.

  • June 18, 2018

    GCs Tackle Law Firm Culture In Diversity Push

    Following an American Bar Association pledge, in-house attorneys are taking a harder line in demanding diversity from their outside counsel, and they're seeking to play a larger role in the workings of the law firms they hire.

  • June 18, 2018

    The Hurdles Facing BigLaw’s Minority Women

    We asked BigLaw for data on female minority lawyers for the first time this year, and the results show an industry that is failing to attract and retain them. Here’s a look at the challenges facing these attorneys — and how a few firms are defying the norm.

  • June 18, 2018

    The Best Firms For Minority Equity Partners

    The legal industry is making sluggish gains when it comes to attracting and retaining attorneys of color, but this select group of firms is taking broader strides to diversify at the top.

  • June 18, 2018

    4 Takeaways From The FDA's Info-Sharing Guidance

    The U.S. Food and Drug Administration recently released finalized guidance loosening restrictions on what information drug and medical device companies can share with insurers and other third-party payors, a development attorneys view as a sign that the agency is softening its stance on off-label promotion.

  • June 18, 2018

    PTAB Rejects Samsung Challenge To Herceptin Patent

    The Patent Trial and Appeal Board on Monday rejected a bid from Samsung Bioepis Co. Ltd. for review of a patent covering the cancer drug Herceptin, finding Samsung’s arguments were essentially the same as other drug companies that challenged the patent.

  • June 18, 2018

    PE-Backed BJ's Leads 9 IPO Launches Exceeding $1.9B

    Private equity-backed BJ's Wholesale Club Holdings Inc. launched an estimated $600 million initial public offering on Monday, leading a flurry of nine companies that set price ranges on IPOs projected to surpass $1.9 billion in proceeds across several industries.

  • June 18, 2018

    Dr. Oz Reaches $5M Settlement Over 'Miracle' Diet Pills

    Television personality Dr. Mehmet Oz agreed to pay $5.25 million in California federal court Friday to settle a proposed class action alleging he misrepresented the effectiveness of weight-loss supplements.

  • June 18, 2018

    In Their Own Words: Minority Partners On Reaching The Top

    Despite decades of industrywide initiatives, movement up the ladder has stagnated for minority lawyers. Here, five industry success stories tell Law360 about the paths they took and what needs to change in BigLaw.

  • June 18, 2018

    Bayer Dodges Yaz, Yasmin Suit After Improper Expert Report

    Pharmaceutical giant Bayer AG knocked down a customer's claims that she developed gallbladder disease after using the company's Yaz and Yasmin birth control pills, after a New Jersey state appeals court on Monday found that shortcomings in her expert report justified nixing her bid to revive the litigation.

  • June 18, 2018

    CITIC Eyes $3.65B Takeover Of US-Listed China Biologic

    An affiliate of Chinese investment firm Citic Capital offered to buy out U.S.-listed China Biologic in a deal that values the plasma-based biopharmaceutical player at $3.65 billion, after building up a stake in the company, according to a Monday filing with the U.S. Securities and Exchange Commission.

  • June 18, 2018

    Ferring Will Face Counterclaims In $165M Patent Deal Row

    A New York federal judge has said two pharmaceutical companies run by former Ferring BV researchers may proceed with counterclaims against their former employer over who owns the intellectual property rights to an antidiuretic, finding that they had enough of a financial interest to challenge the patents.

  • June 18, 2018

    Lindquist Fights Nix Of Arbitration In Laser-Tech Advice Row

    Ballard Spahr LLP acquisition Lindquist & Vennum LLP is asking a Pennsylvania appeals court to consider whether the firm should be allowed to arbitrate claims that it provided faulty legal advice to a medical supply company about its ability to rent out patented laser technology.

  • June 15, 2018

    Minority Lawyers On Why They Left BigLaw

    Despite the proliferation of diversity committees and inclusion initiatives, corporate law firms remain overwhelmingly white and male, especially at leadership levels. Here, minority attorneys discuss their reasons for leaving a large firm.

  • June 15, 2018

    Taking On The ‘Petri Dish’ Of BigLaw Bias

    The often-informal processes for deciding matters like compensation at law firms can create, as one expert put it, a “petri dish” for the effects of unconscious bias. Here’s how some firms are looking to shake up the system.

  • June 15, 2018

    The Best Firms For Minority Attorneys

    While U.S. law firms have long vowed to make their ranks more diverse and inclusive, the industry has long failed to deliver on those promises. Here are the firms making some headway, according to this year’s Diversity Snapshot.

  • June 15, 2018

    Law360’s Diversity Snapshot: By The Numbers

    Efforts to increase diversity have again yielded few meaningful changes in law firm demographics, according to Law360’s annual headcount survey, even as law schools continue to enroll students of color in increasing numbers.

  • June 15, 2018

    Law360’s Pro Say: What BigLaw Should Do About Diversity

    For years law firms have had programs aimed at increasing attorney diversity, but nothing is working. On this week’s Pro Say podcast we take a look at our latest survey of diversity at law firms, and unpack what experts say are the things that could actually move the needle on this issue.

  • June 15, 2018

    FCA Decision Tracker: Continued Interpretations Of Escobar

    Two years after the U.S. Supreme Court's Escobar ruling shook up the legal landscape for False Claims Act cases, Law360’s ninth post-Escobar roundup explores how courts are continuing to address key parts of the decision.

  • June 15, 2018

    Hi-Tech Deserves $40M Sanctions, FTC Tells 11th Circ.

    The Federal Trade Commission asked the Eleventh Circuit to uphold $40 million in sanctions against Hi-Tech Pharmaceuticals Inc. and two executives for allegedly violating an injunction barring them from making unsubstantiated weight-loss claims, saying they knew they were flouting the order.

Expert Analysis

  • Knowledge Lawyers Can Help Firms Stay Ahead Of The Curve

    Vanessa Pinto Villa

    In a profession notoriously averse to change, it should come as no surprise that there is skepticism about the value of having attorneys perform nonbillable tasks. But U.S. law firms have slowly begun to incorporate knowledge lawyers into their operations — and the trend is likely to continue, says Vanessa Pinto Villa of Hogan Lovells.

  • Bristol-Myers Squibb: 1 Year Later

    Adam Pollet

    In the year since the U.S. Supreme Court decided Bristol-Myers Squibb Co. v. Superior Court of California — limiting where plaintiffs can bring claims and curbing forum-shopping in mass tort litigation — courts have grappled with questions that the ruling did not address, and defendants have pursued jurisdictional defenses in class actions and federal cases that were not previously available, say attorneys with Eversheds Sutherland LLP.

  • Insights From State AG Coordinated Opioid Investigation

    Richard Lawson

    Much ink has been and will be spilled over the merits and complexities of the lawsuits brought against opioid manufacturers by 23 state attorneys general. However, for any company engaged in a consumer-facing industry, the progress of the recent multistate investigation offers lessons on what to expect when subject to this type of inquiry, says Richard Lawson of Manatt Phelps & Phillips LLP.

  • An Unprecedented Look Inside The FARA Unit

    Brian Fleming

    For close observers of the Foreign Agents Registration Act, the June 8 release by the U.S. Department of Justice of over 50 FARA advisory opinions was a watershed. These opinions offer an unprecedented glimpse into how the FARA Registration Unit interprets the law, say Brian Fleming and Andrew Herman of Miller & Chevalier Chtd.

  • DEA Hemp Rule Is Safe For Now, But That May Change

    Joshua Mandell

    The Ninth Circuit recently rejected an industry challenge to a U.S. Drug Enforcement Administration rule classifying cannabidiol medicines as Schedule 1 drugs. This decision might chill the CBD boom taking place around the country, but could also spur action at the federal level that would supersede the DEA's rule, say attorneys at Akerman LLP.

  • Options For Failing Marijuana Cos. And Their Creditors

    Brett Theisen

    In the marijuana industry, there is ambiguity surrounding failing businesses because the product remains illegal under federal law. Brett Theisen of Gibbons PC identifies the credit risks associated with lending to, or working with, a marijuana business and highlights key state law solutions for both debtors and creditors.

  • A Farxiga Opinion That's All Hat, No Cattle

    Lora Spencer

    Is everything really bigger in Texas? A New York federal court's ruling in Aron v. Bristol-Myers Squibb — apparently the first reported opinion from the Farxiga multidistrict litigation — would have us believe that pharmaceutical manufacturers have bigger tort liability under Texas law. But the court let the plaintiffs slide on a number of key points, says Lora Spencer of Reed Smith LLP.

  • Cures Revolution May Reshape Pharmaceutical Landscape

    David Hoffmeister

    The advent of therapeutics that cure diseases rather than merely treating their symptoms is likely to usher in a cures revolution that will present significant growth opportunities for pharmaceutical companies and impact patients, regulators and governments as well, say attorneys at Wilson Sonsini Goodrich & Rosati PC and Jeff Galvin of American Gene Technologies.

  • Why Lawyers Shouldn't Accept Fees In Cryptocurrency: Part 2

    John Reed Stark

    The legal industry has already begun to feel the impact of anti-bribery and anti-money laundering requirements. When involved with cryptocurrency trading and remittance, law firms face more than the risk of being perceived as organizations that support money laundering practices, says John Reed Stark of John Reed Stark Consulting LLC.

  • Why Lawyers Shouldn't Accept Fees In Cryptocurrency: Part 1

    John Reed Stark

    Law firms are increasingly accepting cryptocurrency as payment for services. While this might seem innovative and forward-thinking, ironically it is much more of a throwback, says John Reed Stark of John Reed Stark Consulting LLC.